Center-Authored Papers

Filters: Author is Modugno, Francesmary  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
U
Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, Defazio A, Risch HA, Rossing MA et al..  2017.  Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.. British journal of cancer. Abstract
T
Earp M, Winham SJ, Larson N, Permuth JB, Sicotte H, Chien J, Anton-Culver H, Bandera EV, Berchuck A, Cook LS et al..  2016.  A targeted genetic association study of epithelial ovarian cancer susceptibility.. Oncotarget. 7(7):7381-7389. Abstract
S
Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT, Rossing MA, Modugno F, Moysich KB, Chang-Claude J et al..  2016.  A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.. International journal of cancer. Abstract
Lu Y, Cuellar G, Painter JN, Nyholt D, Morris AP, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D et al..  2015.  Shared genetics underlying epidemiological association between endometriosis and ovarian cancer.. Human molecular genetics. 24(20):5955-5964. Abstract
R
Thomson CA, Neuhouser ML, Shikany JM, Caan BJ, Monk BJ, Mossavar-Rahmani Y, Sarto G, Parker LM, Modugno F, Anderson GL.  2008.  The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative.. Nutrition and cancer. 60(6):710-9. Abstract
Clyde MA, Weber RP, Iversen ES, Poole EM, Doherty JA, Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL et al..  2016.  Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.. American journal of epidemiology. 184(8):579-589. Abstract
Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E et al..  2013.  Risk of Ovarian Cancer and the NF-κB Pathway: Genetic association with IL1A and TNFSF10.. Cancer research. Abstract
McTiernan A, Wu LL, Barnabei VM, Chen C, Hendrix S, Modugno F, Rohan T, Stanczyk FZ, Wang C-Y.  2008.  Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women.. Breast cancer research and treatment. 108(2):217-31. Abstract
Cannioto RA, Lamonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong C-C, Szender BJ, Sucheston-Campbell L, Joseph JM et al..  2016.  Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.. British journal of cancer. Abstract
P
Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Lee AW, Menon U, Fasching PA, McAlpine JN et al..  2015.  Population distribution of lifetime risk of ovarian cancer in the United States.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 24(4):671-6. Abstract
Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ et al..  2016.  PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.. Journal of medical genetics. Abstract
N
Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender BJ, Minlikeeva A et al..  2016.  No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H et al..  2016.  No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. 141(2):386-401. Abstract
Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KKH, Anton-Culver H, Antonenkova N, Chenevix-Trench G, Baker H, Bandera E et al..  2015.  Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 24(10):1574-1584. Abstract
M
Babic A, Harris HR, Vitonis AF, Titus LJ, Jordan SJ, Webb PM, Risch HA, Rossing MA, Doherty JA, Wicklund K et al..  2017.  Menstrual pain and risk of epithelial ovarian cancer: results from the Ovarian Cancer Association Consortium.. International journal of cancer. Abstract
I
Winham SJ, Pirie A, Chen YA, Larson MC, Fogarty ZC, Earp MA, Anton-Culver H, Bandera EV, Cramer D, Doherty JA et al..  2016.  Investigation of exomic variants associated with overall survival in ovarian cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Permuth JB, Reid B, Earp M, Chen AY, Monteiro ANA, Chen Z, Chen Z, Chenevix-Trench G, Fasching PA, Beckmann MW et al..  2016.  Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.. Oncotarget. 7(45):72381-72394. Abstract
Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM et al..  2015.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer.. Nature genetics. 47(2):164-71. Abstract
Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G et al..  2017.  Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.. Nature genetics. Abstract
Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin H-Y, Chen AY, Tsai Y-Y, Qu X et al..  2013.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.. Nature communications. 4:1627. Abstract
H
Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender BJ, Mayor P, Etter JL, Cramer DW, Diergaarde B, Doherty JA et al..  2017.  History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.. British journal of cancer. Abstract
Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender BJ, Eng KH, Modugno F, Ness RB, Lamonte MJ, Friel G, Segal BH et al..  2017.  History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.. Cancer causes & control : CCC. Abstract
Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender BJ, Segal B, Odunsi K, Mayor P, Diergaarde B et al..  2017.  History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 26(9):1470-1473. Abstract
G
Pharoah PDP, Tsai Y-Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H et al..  2013.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.. Nature genetics. 45(4):362-70,370e1-2. Abstract
Kar SP, Beesley J, Al Olama AA, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ et al..  2016.  Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.. Cancer discovery. 6(9):1052-1067. Abstract